PDCD1 and non-small cell lung carcinoma: Therapeutic antibodies against programmed cell death-1 (PD-1) and programmed cell death-ligand 1 (PD-L1) are one of the most important forms of ICB and are approved as the first-line treatment for patients with advanced or metastatic NSCLC (3).